12:53:12 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-07-18 Kvartalsrapport 2023-Q2
2023-06-21 Ordinarie utdelning ZICC 0.00 SEK
2023-06-20 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-01-27 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning ZICC 0.00 SEK
2022-04-28 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2022-01-18 Extra Bolagsstämma 2022
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-04-28 Ordinarie utdelning ZICC 0.00 SEK
2021-04-27 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-11-06 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Ordinarie utdelning ZICC 0.00 SEK
2020-06-16 Årsstämma 2020
2020-04-17 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-20 Årsstämma 2019
2019-05-10 Ordinarie utdelning ZICC 0.00 SEK
2019-05-09 Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst versamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2022-09-27 08:30:00

Ziccum AB (publ) (‘Ziccum’) today announces that is has reopened its application process for CEPI’s Call for Proposals (CfP) from companies developing innovative technologies to improve vaccine thermostability. Ziccum will submit an Expression of Interest (EoI) with a new partner – a well-established, innovative biotechnology company.

Ziccum will now be submitting a formal EoI, together with a new partner, to CEPI’s Call for Proposals for companies developing innovative technologies to improve vaccine thermostability. The partner is a well-established biotech company with novel technology and extensive experience within mRNA vaccine formulation and development.

Ziccum previously communicated (July 21, 2022) that it had decided not to apply for the CEPI funding, not having a relevant partner for the international implementation of manufacturing. Subsequent to that decision, Ziccum has been approached by this biotechnology partner to develop a joint application to improve vaccine thermostability. The CEPI CfP targets manufacturing organizations that can implement thermostable vaccine facilities globally.

Ziccum CEO Ann Gidner: “This is a very good union with a shared commitment to innovation in mRNA vaccines. The expertise and capabilities on our partner’s side are solid, inspiring and exciting. We look forward to completing our application.”

About CEPI: CEPI, the Coalition for Epidemic Preparedness Innovations, funds a wide range of research projects to develop vaccines through donations from public, private, charitable and civil society organizations. CEPI is headquartered in Oslo, Norway.